Gelonghui, April 26 | Shanghai Pharmaceutical (02607.HK) announced that in the first quarter of 2024, during the reporting period, the company's main business grew steadily, achieving operating revenue of 70.153 billion yuan (currency is RMB, same below), an increase of 5.93% over the previous year. Among them, the pharmaceutical industry achieved sales revenue of 6.944 billion yuan, a year-on-year decrease of 10.98%; the pharmaceutical business achieved sales revenue of 63.209 billion yuan, an increase of 8.19% over the previous year.
During the reporting period, the company achieved net profit attributable to shareholders of listed companies of 1,542 billion yuan, a year-on-year increase of 1.62%, of which industrial business contributed 674 million yuan, a year-on-year decrease of 4.06%; commercial business contributed 832 million yuan, an increase of 0.50%; and major shareholders contributed 185 million yuan in profit, a year-on-year decrease of 11.29%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was $1,375 million, an increase of 1.30% over the previous year.
During the reporting period, the company invested 715 million yuan in R&D, an increase of 30.78% over the previous year, of which 501 million yuan was spent on R&D.